IDEXX Lifts 2026 Outlook as Q3 EPS Rises 18% to $4.01 on 11% Recurring Diagnostics Growth
Revenue rose 10% to $1.214B and operating margin expanded to 33.1%, but the company trimmed its full-year margin outlook as it invests in growth.
IDEXX Laboratories (IDXX) reported third-quarter revenue of $1.214 billion, up 10% on both a reported and organic basis, and EPS of $4.01, up 18% reported and 22% on a comparable basis. Results beat expectations of about $3.71 in EPS and $1.19 billion in revenue, according to a published preview, and the veterinary diagnostics company raised its 2026 revenue and EPS outlook. Shares rose about 5.5% in premarket trading Monday.
Third-quarter results
| Metric | Q3 2026 | Context |
|---|---|---|
| Revenue | $1.214B | Up 10%; consensus about $1.19B, a beat of roughly 2%, by our calculation |
| EPS | $4.01 | Up 18% reported; consensus about $3.71, a beat of about 8%, by our calculation |
| Gross margin | 62.9% | Up 110 basis points |
| Operating margin | 33.1% | Up 100 basis points reported, 60 comparable |
| Free cash flow | $420.8M | Up from $371.2M a year earlier |
| Share repurchases | About $112M | About 199,000 shares in Q3 |
EPS included a $0.03 gain from an equity investment and a $0.04 currency benefit. Operating expenses rose 10% on commercial investment, innovation spending and acquisition costs. Nine-month free cash flow was $977.6 million and nine-month repurchases were about $816 million.
What drove growth
| Area | Growth |
|---|---|
| Companion Animal Group (CAG) Diagnostics recurring revenue | Up 11% reported and organic |
| U.S. recurring | Up 10% |
| International recurring | Up 13% reported, 14% organic |
| VetLab consumables | Up 14% reported, 15% organic |
| Reference lab services | Up 10% |
| Rapid assay | Up 1% |
| Capital instruments | Flat |
| Water | Up 8% |
| Livestock, Poultry and Dairy | Up 3% |
Recurring revenue, the testing and consumables that run on IDEXX's installed instruments, remained the engine. The company placed more than 1,900 inVue Dx analyzers in the quarter, bringing that installed base to nearly 11,000, and its premium instrument installed base grew 11%. More instruments in clinics typically support future consumable sales.
Updated 2026 outlook
| Item | New outlook | Prior outlook |
|---|---|---|
| Revenue | $4,741M to $4,767M | $4,700M to $4,745M |
| Organic revenue growth | 9.3% to 10.0% | 8.5% to 9.7% |
| CAG Diagnostics recurring growth | 11.0% to 11.7% reported | Raised from prior range |
| EPS | $14.96 to $15.16 | $14.69 to $14.94 |
| Operating margin | 32.1% to 32.3% | 32.3% to 32.5% |
| Free cash flow | 95% to 100% of net income | 90% to 100% |
| Capital expenditures | About $160M | About $180M |
By our calculation, the new EPS midpoint of $15.06 is about $0.25 above the prior midpoint and about 2.6% above a full-year consensus near $14.68 ahead of the report. The operating margin outlook was lowered, which the company tied to its investment plans. The outlook includes about $5 million of revenue from CoVet, an AI clinical assistant for veterinary teams that IDEXX acquired.
Management commentary
CEO Mike Erickson said IDEXX delivered "exceptional third quarter results." The company will hold an investor session on its upcoming MultiCue Dx analyzer on Jan. 18, 2027, in Orlando.
What to watch
- Veterinary visit trends. Management had expected U.S. clinic visits to decline roughly 1.5% in the second half, so testing per visit has to keep growing to deliver the outlook.
- Margins. The lowered full-year operating margin outlook leaves less cushion if investment spending runs higher.
- Instruments. Capital instrument revenue was flat, so placements and the MultiCue Dx launch matter for future consumable sales.
- Valuation reaction. Premarket gains need to hold through the session. See the full week's calendar in our Week Ahead article, and the market backdrop in our Research Desk analysis.
Sources: IDEXX Laboratories' third-quarter 2026 results announcement. Consensus estimates and the premarket move are from market data and a published earnings preview and will change. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.
Readers also read
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.